Abstract: In an embodiment, a method for controlling a printer is provided. The method includes: receiving a set of parameters associated with a printer by a computing device, wherein the printer is depositing ink on a substrate to generate a line; measuring a width of the line by the computing device; receiving a duty cycle associated with the printer by the computing device; using the received duty cycle, the set of parameters, and a model, estimating one or more unknown parameters of the set of parameters by the computing device; receiving a desired width of the line by the computing device; and if the desired width is not the same as the measured width: adjusting the duty cycle associated with the printer based on the set of parameters and the model so that the measured width is closer to the desired width by the computing device.

Abstract: Disclosed herein are methods of annealing a perovskite layer, comprising irradiating the perovskite layer with a light source, wherein the light source emits radiation consisting essentially of wavelengths within 50 nm of the wavelength of maximum absorbance (?max) of the perovskite layer, thereby annealing the perovskite layer. Also disclosed herein are semiconducting devices and articles of manufacture comprising an annealed perovskite layer made by any of the methods described herein, such as solar cells, light-emitting diodes, photodetectors, thin-film transistors, and combinations thereof.

Abstract: A lasing device includes an active layer comprising a cholesteric liquid crystal material and a laser dye, and a liquid crystal cell including spaced apart substrates defining a cell gap in which the active layer is disposed. The substrates include electrodes arranged to bias the active layer into an oblique helicoidal (ChOH) state. At least one substrate of the liquid crystal cell is optically transparent for a lasing wavelength range of the device.

Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.

Abstract: he disclosure relates to the engineering of collagen-binding modification of masked therapeutic agents comprising one or more tumor-associated protease cleavage sites. Upon exposure to tumor-associated proteases in the tumor microenvironment, the polypeptide is cleaved, which unmasks the therapeutic agent, reducing off-target side effects and toxicity associated with systemic administration. Accordingly, aspects of the disclosure relate to a polypeptide comprising a therapeutic agent linked to a masking agent through a linker, wherein the linker comprises one or more tumor-associated protease cleavage sites, and wherein the masking agent blocks the association of the therapeutic agent to its therapeutic target, and further wherein the polypeptide is operatively linked to a collagen binding domain or a tumor-targeting agent.

Abstract: Methods for controlling for non-systematic error in an amplification-based next generation sequencing (NGS) library preparation are described, which method includes using an internal amplification control (IAC) sharing identical priming sites to a native nucleic acid target template of interest in a NGS library preparation.

Abstract: Bioactive glass compositions, composites of the bioactive glass compositions with polymers, and 3D printable filaments made from the same, along with methods of making and using the same, are described. In some embodiments, the compositions, composites, and filaments have antibacterial activity.

Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.

Abstract: An implant can include a plurality of polymeric fibers associated together into a fibrous body. The fibrous body is capable of being shaped to fit a tracheal defect and capable of being secured in place by suture or by bioadhesive. The fibrous body can have aligned fibers (e.g., circumferentially aligned) or unaligned fibers. The fibrous body can be electrospun. The fibrous body can have a first characteristic in a first gradient distribution across at least a portion of the fibrous body. The fibrous body can include one or more structural reinforcing members, such as ribbon structural reinforcing members, which can be embedded in the plurality of fibers. The fibrous body can include one or more structural reinforcing members bonded to the fibers with liquid polymer as an adhesive, the liquid polymer having a substantially similar composition of the fibers.

Abstract: Identification and evaluation of a set of first-in-class potent inhibitors targeting a new cancer target, Grb2-associated binder-1 (GAB1), which integrates signals from different signaling pathways and is frequently over-expressed in cancer cells. Intensive computational modeling is utilized to understand the structure of the GAB1 pleckstrin homology (PH) domain and screened five million compounds. Upon biological evaluation, several inhibitors were found that induced large conformational changes of the target structure exhibited strong selective binding to GAB1 PH domain. Particularly, these inhibitors demonstrated potent and tumor-specific cytotoxicity in breast cancer cells. This targeting GAB1 signaling may be used for cancer therapy, especially for triple negative breast cancer patients.

Abstract: A wave receiving plate is pivotably supported by a support device in the wave force generation system and includes a flexible plate in at least a part of the wave receiving plate.

Abstract: The present disclosure relates to methods for inhibiting activation of ?? T cells that express a V?9+ TCR in a subject by administering a BTN2A1 antagonist to a subject as well as methods for inducing or enhancing ?? T cells that express a V?9+ TCR in a subject by administering a BTN2A1 antagonist to a subject. The disclosure additionally relates to BTN2A1 antagonists and BTN2A1 agonists.

Abstract: The present invention provides a delivery matrix comprising a carbohydrate derivative and at least one semiochemical for trapping and/or attracting and/or deterring at least one aquatic organism. The present invention provides a method for trapping and/or attracting a crustacean, said method comprising delivering an effective amount of specific semiochemicals.

Abstract: Disclosed herein are methods and devices for the inactivation of pathogens (e.g., bacteria, viruses, etc.) in ex vivo stored blood products, such as plasma and/or platelets, by means of directing visible light radiation from an illuminating device into blood product storage containers in order to achieve effective pathogen inactivation without the presence of an added photosensitising agent in the blood product. An exemplary apparatus includes a control unit that operates a light source that emits light in the wavelength region of about 380-500 nm which is directed onto blood product storage bags at sufficient intensity to penetrate the bag material and the opaque blood product therein in order to inactivate pathogens in the blood product but at dose levels that cause no significant detrimental effects on the blood product.

Abstract: A vat resin for three-dimensional stereolithography printing of a thiourethane polymer part comprising a liquid mixture including a first type of monomer, a second type of monomer, a photolatent base decomposable upon exposure to a light to form a non-nucleophillic base catalyst having a pKa greater than 7, an anionic step-growth polymerization reaction inhibitor having an acidic group configured to form an acid-base pair with the non-nucleophillic base and a light absorber having an absorbance in the liquid mixture that is greater than an absorbance of the photolatent base at a wavelength of the light used for the exposure. Methods of preparing the vat resin and three-dimensional stereolithography printing a thiourethane polymer part using the vat resin are also disclosed.

Abstract: Disclosed herein are dendritically porous three-dimensional structures, including hierarchical dendritically porous three-dimensional structures. The structures include metal foams and graphite structures, and are useful in energy storage devices as well as chemical catalysis.

Abstract: This disclosure provides multimeric binding molecules that bind to SARS-CoV-2. This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating and preventing coronavirus disease 2019 (COVID-19).

Abstract: ‘V84031’ is a self-fruitful sweet cherry tree distinguished by its early flowering and large mahogany-colored fruit.

Abstract: A method of treating or preventing a sickle cell disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting immature hematopoietic cells into the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of non-GVHD inducing anti-third party cells comprising cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and capable of homing to the lymph nodes following transplantation.

Abstract: Embodiments of the present disclosure pertain to methods of monitoring an environment for the presence of a solvent by: (i) exposing the environment to a luminescent compound, where the relative luminescence emission intensity of the luminescent compound changes upon interaction with the solvent; and (ii) monitoring a change in the relative luminescence emission intensity of the luminescent compound, where the absence of the change indicates the absence of the solvent from the environment, and where the presence of the change indicates the presence of the solvent in the environment. The luminescent compounds include a phosphorous atom with one or more carboxyl groups, where the carboxyl groups are coordinated with one or more metallic ions (e.g., lanthanide ions and yttrium ions). The present disclosure also pertains to sensors for monitoring an environment for the presence of a solvent, where the sensors include one or more of the aforementioned luminescent compounds.